Immunome (IMNM) Share-based Compensation (2019 - 2026)
Immunome's (IMNM) quarterly Share-based Compensation came in at $8.0 million in Q1 2026, up 39.45% YoY from $5.7 million in Q1 2025, and up 0.76% on a QoQ basis from $7.9 million in Q4 2025.
Immunome (IMNM) Share-based Compensation (2019 - 2026) Analysis & Trends
Immunome (IMNM) has 8 years of Share-based Compensation data on file, last reported at $8.0 million in Q1 2026.
- Quarterly Share-based Compensation rose 39.45% year-over-year to $8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.9 million (up 44.83% YoY) and the FY2025 annual result came in at $81.5 million, up 8.38% from the prior year.
- Share-based Compensation advanced to $8.0 million in Q1 2026, from $7.9 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $8.0 million in Q1 2026 to a low of $1.0 million in Q2 2023.
- A 5-year average of $3.5 million and a median of $2.2 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation dropped 22.16% — and 2024, when it soared 395.47%.
- Tracing IMNM's Share-based Compensation over 5 years: stood at $1.4 million in 2022, then fell by 18.52% to $1.1 million in 2023, then soared by 395.47% to $5.5 million in 2024, then soared by 44.3% to $7.9 million in 2025, then rose by 0.76% to $8.0 million in 2026.
- The last three Share-based Compensation figures came in at $8.0 million (Q1 2026), $7.9 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Immunome | 3.09 Bn | 2.57 Bn | - | 89.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 89.80 Mn |
| Jun 30, 2026 | 89.80 Mn |
| Mar 31, 2026 | 7.95 Mn |
| Mar 31, 2026 | 7.95 Mn |
| Dec 31, 2025 | 7.89 Mn |
| Dec 31, 2025 | 7.89 Mn |
| Sep 30, 2025 | 6.75 Mn |
| Sep 30, 2025 | 6.75 Mn |
| Jun 30, 2025 | 5.35 Mn |
| Jun 30, 2025 | 5.35 Mn |
| Mar 31, 2025 | 5.70 Mn |
| Mar 31, 2025 | 5.70 Mn |
| Dec 31, 2024 | 5.47 Mn |
| Dec 31, 2024 | 5.47 Mn |
| Sep 30, 2024 | 4.89 Mn |
| Sep 30, 2024 | 4.89 Mn |
| Jun 30, 2024 | 3.23 Mn |
| Jun 30, 2024 | 3.23 Mn |
| Mar 31, 2024 | 2.16 Mn |
| Mar 31, 2024 | 2.16 Mn |